Esketamine · Spravato

Small molecule

Also known as JNJ-54135419

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CN
  • Adults with depression with acute suicidal thoughts or behavior, taken with an oral antidepressant (per trade report; label wording not seen)
Product first approved 2023yicaiglobal.com
CA
  • MDD in adults who have not responded adequately to at least two courses of antidepressants, with an SSRI or SNRI
Product first approved 2020dhpp.hpfb-dgpsa.ca
EU
  • Treatment-resistant major depressive disorder in adults, with an SSRI or SNRI (EU 2021 extension: acute short-term treatment of a psychiatric emergency in moderate to severe MDD)
Product first approved 2019EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (17)
Major Depressive Disorder
NCT07227454 · Janssen Research & Development, LLC
2026-01-08 – 2031-09-15 · Depressive Disorder, Major
What this study did
NCT07716098 · Janssen Research & Development, LLC
2026-07-23 – 2029-09-12 · Depressive Disorder, Treatment-Resistant
What this study did
NCT07153406 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2025-09-15 – 2029-01-15 · Depressive Disorder
What this study did
NCT04924257 · Medical University Innsbruck
2021-07-28 – 2024-04 · Treatment Resistant Depression, Major Depressive Disorder
What this study did
NCT03434041 · Janssen Research & Development, LLC
2018-05-25 – 2021-04-13 · Depressive Disorder, Treatment-Resistant
What this study did
NCT02493868 · Janssen Research & Development, LLC
2015-10-01 – 2018-02-16 · Depressive Disorder, Treatment-Resistant
What this study did
NCT02497287 · Janssen Research & Development, LLC
2015-09-30 – 2017-10-28 · Treatment-resistant Depression
What this study did
NCT02422186 · Janssen Research & Development, LLC
2015-08-20 – 2017-08-10 · Depressive Disorder, Treatment-Resistant
What this study did
Other / comorbidity
NCT06713616 · Yale University
2025-01-27 – 2030-12-31 · Depression
What this study did
Phase 2 (8)
Major Depressive Disorder
NCT05438758 · Zylorion Health
2023-01-15 – 2024-03-01 · Treatment Resistant Major Depressive Disorder
What this study did
NCT05323019 · Zylorion Health
2022-10-13 – 2023-02-01 · Treatment Resistant Major Depressive Disorder
What this study did
NCT02918318 · Janssen Pharmaceutical K.K.
2016-12-12 – 2019-12-13 · Depression
What this study did
NCT01998958 · Janssen Research & Development, LLC
2014-01-27 – 2015-09-25 · Treatment Resistant Depressive Disorder
What this study did
NCT01640080 · Janssen Research & Development, LLC
2012-06-27 – 2013-06-03 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT04666623 · University Hospital, Basel, Switzerland
2020-11-25 – 2023-10-11 · Cancer Pain
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06795659 · The University of Texas Health Science Center at San Antonio
2025-06-09 – 2026-01-16 · Post Traumatic Stress Disorder PTSD
What this study did
Phase 1 (25)
Major Depressive Disorder
NCT02919579 · Janssen Research & Development, LLC
2016-10-07 – 2018-06-29 · Depressive Disorder, Major
What this study did
Other / comorbidity
NCT05464979 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2022-08-27 – 2023-06-28 · Critically Ill Patients
What this study did
NCT05320120 · Rupert Lanzenberger
2022-06-01 – 2023-06-21 · Ketamine Treatment
What this study did
NCT04282746 · Janssen Research & Development, LLC
2020-02-18 – 2020-08-17 · Healthy
What this study did
NCT04300621 · Janssen Research & Development, LLC
2020-06-19 – 2020-08-10 · Healthy
What this study did
NCT03808259 · Janssen Research & Development, LLC
2018-12-20 – 2019-09-04 · Healthy
What this study did
NCT02606084 · Janssen Research & Development, LLC
2015-12-04 – 2018-02-02 · Renal Impairment, Healthy
What this study did
NCT03298906 · Janssen Research & Development, LLC
2017-09-26 – 2017-11-27 · Healthy
What this study did
NCT02611505 · Janssen Research & Development, LLC
2015-11-30 – 2017-02-27 · Hepatic Impairment, Normal Hepatic Function
What this study did
NCT02737605 · Janssen Research & Development, LLC
2016-07-01 – 2017-02-23 · Healthy
What this study did
NCT02857777 · Janssen Research & Development, LLC
2016-08-09 – 2017-01-27 · Healthy
What this study did
NCT02682225 · Janssen Research & Development, LLC
2016-03-25 – 2017-01-09 · Drug Abuse
What this study did
NCT02674295 · Janssen Research & Development, LLC
2016-03 – 2016-08 · Healthy
What this study did
NCT02568176 · Janssen Research & Development, LLC
2015-10 – 2016-02 · Healthy
What this study did
NCT02345148 · Janssen Research & Development, LLC
2014-12 – 2015-01 · Healthy
What this study did
NCT02228239 · Janssen Research & Development, LLC
2014-09 – 2014-12 · Healthy
What this study did
NCT02154334 · Janssen Research & Development, LLC
2014-06 – 2014-10 · Allergic Rhinitis
What this study did
NCT02094378 · Janssen Research & Development, LLC
2014-06 – 2014-08 · Healthy
What this study did
NCT02129088 · Janssen Research & Development, LLC
2014-03 – 2014-05 · Healthy
What this study did
NCT01980303 · Janssen Research & Development, LLC
2013-11 – 2014-01 · Healthy Volunteers
What this study did
NCT02060929 · Janssen Research & Development, LLC
2013-10 – 2014-01 · Healthy
What this study did
NCT01780259 · Janssen Research & Development, LLC
2012-12 – 2013-05 · Healthy
What this study did
Phase 4 (11)
Major Depressive Disorder
NCT06103760 · Royal North Shore Hospital
2023-10-31 – 2028-08-15 · Major Depressive Disorder
What this study did
NCT06278779 · The George Institute
2024-06-03 – 2027-04 · Treatment Resistant Depression
What this study did
NCT07053345 · Janssen Korea, Ltd., Korea
2025-06-09 – 2026-07-13 · Depressive Disorder, Treatment-Resistant
What this study did
NCT04829318 · Janssen-Cilag Ltd.
2021-04-26 – 2024-07-22 · Depressive Disorder, Major
What this study did
NCT05554627 · VA Office of Research and Development
2023-10-27 – 2023-10-27 · Depressive Disorder, Major
What this study did
Other / comorbidity
NCT07639099 · Peking University First Hospital
2026-06 – 2029-12 · Parturients, Depressive Symptoms, Esketamine, Dexmedetomidine, Intranasal Administration, Postpartum Depression
What this study did
NCT07934901 · Peking University First Hospital
2026-11 – 2028-05 · Postherpetic Neuralgia, Esketamine, Dexmedetomidine, Intranasal Administration, Analgesic Efficacy
What this study did
NCT05180318 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-10-01 – 2024-12-31 · Surgical Injury
What this study did
NCT05925283 · Second Affiliated Hospital of Wenzhou Medical University
2023-06-30 – 2024-03-30 · Anxiety
What this study did
NCT03421275 · Anna Meuronen, MD
2017-12-01 – 2022-12-01 · Acute Pain Due to Trauma
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT06432322 · University of Oxford
2024-06-14 – 2025-03-26 · Depression
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT07317206 · University of Sao Paulo
2025-12-20 – 2026-07 · Posttraumatic Stress Disorder (PTSD)
What this study did
Phase 1 (2)
Other / comorbidity
NCT07910838 · University of Sao Paulo
2023-06-01 – 2025-07-30 · Healthy Adult Participants
What this study did
NCT06726382 · Helsinki University Central Hospital
2024-12-09 – 2025-04-29 · Drug Interactions, Food-drug Interaction
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT07317219 · University of Sao Paulo
2025-12-20 – 2026-07 · Healthy Women Volunteers
What this study did
NCT07317232 · University of Sao Paulo
2025-12-20 – 2026-07 · Healthy Women Volunteers
What this study did
NCT07050212 · Maternal and Child Health Hospital of Hubei Province
2025-04-01 – 2026-03-01 · Remimazolam, Dexmedetomidine, Esketamine
What this study did
Appears in other studies (228)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (7)
Major Depressive Disorder
NCT05973851 · Dr. Inge Winter
2024-08-31 – 2028-06-30 · Major Depressive Disorder, Treatment Resistant Depression
What this study did
NCT05603104 · Dr. Inge Winter
2025-04-27 – 2026-06-24 · Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
What this study did
Other / comorbidity
NCT06051227 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2024-01-11 – 2026-08-06 · Acute Pain Due to Trauma, Analgesia, Fentanyl, Esketamine, Emergency Medical Services
What this study did
NCT06161805 · Reinier de Graaf Groep
2024-03-01 – 2026-06-01 · Endometriosis, Chronic Pelvic Pain Syndrome
What this study did
NCT05839366 · Nanfang Hospital, Southern Medical University
2023-05-31 – 2024-10-31 · Septic Shock, Mechanical Ventilation Complication
What this study did
NCT06092684 · Chengdu Brilliant Pharmaceutical Co., Ltd.
2023-09-20 – 2024-03-19 · Laparoscopy, Anesthesia, Intravenous
What this study did
NCT01022840 · Medical University of Graz
2009-02 – 2012-09 · Pain
What this study did
Phase 2/3 (5)
Other / comorbidity
NCT04425473 · Beijing Tiantan Hospital
2021-02-19 – 2024-11-27 · Depressive Symptoms, Esketamine, Perioperative Complication, Major Surgery
What this study did
NCT06117917 · Beijing Tiantan Hospital
2023-11-10 – 2024-06-30 · Esketamine, Pregabaline, Chronic Post Operative Pain
What this study did
NCT05160493 · Beijing Tiantan Hospital
2021-12-20 – 2024-06-20 · Chronic Postsurgical Pain
What this study did
NCT05096468 · Beijing Tiantan Hospital
2021-12-01 – 2022-10-15 · Esketamine, Pregabalin, Acute Postoperative Pain, Neurosurgical Procedures, Perioperative Complication, Spinal Cord Neoplasms
What this study did
NCT01275547 · University Hospital, Basel, Switzerland
2011-01 – 2011-12 · Analgesia, Patient-controlled, Spinal Stenosis
What this study did
Phase 2 (11)
Major Depressive Disorder
NCT07949500 · Rodolfo Furlan Damiano
2026-12-01 – 2027-12 · Treatment Resistant Depression (TRD)
What this study did
NCT07212946 · University of Sao Paulo
2022-10-30 – 2025-10-01 · Major Depression Severe
What this study did
NCT03965858 · Celon Pharma SA
2019-02-25 – 2020-04-24 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07888933 · University of Sao Paulo
2027-04-30 – 2029-03-30 · Suicidal Ideation, Suicidal Behavior
What this study did
NCT06744361 · Christian Hassager
2024-12-12 – 2027-09-01 · Out-of-hospital Cardiac Arrest (OHCA)
What this study did
NCT06633315 · Maternal and Child Health Hospital of Hubei Province
2022-12-01 – 2024-09-01 · Autism Spectrum Disorder, Dexmedetomidine, Esketamine, Sedation
What this study did
NCT05092152 · Federal University of São Paulo
2021-10-23 – 2023-12-31 · Acute Respiratory Failure
What this study did
NCT05635955 · Maternal and Child Health Hospital of Hubei Province
2022-08-01 – 2022-09-30 · Anesthesia, Abortion Early
What this study did
NCT03965871 · Celon Pharma SA
2019-03-28 – 2021-02-19 · Bipolar Depression
What this study did
NCT02717052 · Medical University of Vienna
2016-05 – 2019-12-31 · Depression, Ketamine
What this study did
NCT03231683 · KK Women's and Children's Hospital
2014-03 – 2016-05 · Ketamine, Anesthesia, Morphine, Hysterectomy
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT07034963 · The First Affiliated Hospital of Xiamen University
2025-06-26 – 2028-06-30 · Intrauterine Polyp, Intrauterine Synechiae
What this study did
NCT07034950 · The First Affiliated Hospital of Xiamen University
2025-06-29 – 2028-06-30 · Hepatic Neoplasm, Hepatic Cancer
What this study did
NCT06920576 · The Second People's Hospital of Huai'an
2025-03-01 – 2025-07-20 · Chronic Rhinosinusitis, Enhanced Recovery After Surgery
What this study did
Phase 1 (15)
Major Depressive Disorder
NCT06784388 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-01-05 – 2028-12-30 · Treatment-resistant Depression (TRD)
What this study did
NCT04587778 · Medical University of Vienna
2020-10-05 – 2025-03-31 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07247968 · Min Su
2025-11-25 – 2026-12-20 · Esketamine, ECT, Depression, Adolescent
What this study did
NCT06199700 · Children's Hospital of Fudan University
2023-11-15 – 2025-12-30 · Rett Syndrome
What this study did
NCT05242692 · Affiliated Cancer Hospital & Institute of Guangzhou Medical University
2022-06-10 – 2025-08-31 · Postoperative Delirium, Elderly Patients
What this study did
NCT06559280 · Fujian Provincial Hospital
2024-08-24 – 2025-08-20 · Ectopic Pregnancy
What this study did
NCT06073015 · Henan Provincial People's Hospital
2023-10-10 – 2025-02-10 · Anxiety-depression
What this study did
NCT05943028 · bo xu
2023-07-01 – 2024-10-01 · Esketamine
What this study did
NCT05571176 · Elina Brinck
2023-01 – 2023-12 · The Effect of S-ketamine on Pharmacokinetics of Morphine, Hydromorphone, and Buprenorphine
What this study did
NCT06370130 · Aerospace Center Hospital
2022-05-01 – 2023-03-10 · Anesthesia
What this study did
NCT04777110 · First Affiliated Hospital of Chongqing Medical University
2021-08 – 2022-12 · Esketamine, ECT, Depression
What this study did
NCT04745286 · Beijing Tiantan Hospital
2021-03 – 2022-03 · Atelectasis
What this study did
NCT04757675 · Eye & ENT Hospital of Fudan University
2021-03-01 – 2022-01-01 · Emotions, Separation Anxiety, Pain, Procedural
What this study did
NCT03407872 · Celon Pharma SA
2017-12-09 – 2018-06-19 · Healthy Volunteers
What this study did
NCT00847418 · University Hospital, Basel, Switzerland
2009-02 – 2009-10 · Pain
What this study did
Phase 4 (80)
Major Depressive Disorder
NCT05450432 · Massachusetts General Hospital
2022-10-13 – 2027-06-01 · Major Depressive Disorder
What this study did
NCT07369102 · University of Puerto Rico
2026-02-01 – 2026-12-01 · Treatment-resistant Depression (TRD)
What this study did
Other / comorbidity
NCT07576543 · Peking University First Hospital
2026-10 – 2031-12 · Older Patients, Surgery, Dexmedetomidine, Esketamine, Transcranial Direct Current Stimulation, Cognitive Function, Survival
What this study did
NCT07881562 · Region Skane
2028-01-01 – 2031-03-31 · Endometriosis
What this study did
NCT07576517 · Peking University First Hospital
2026-10 – 2030-12 · Older Patients, Surgery, Dexmedetomidine, Esketamine, Transcranial Direct Current Stimulation, Perioperative Neurocognitive Disorders
What this study did
NCT07753772 · Peking University First Hospital
2026-11 – 2030-11 · Ureteral Stricture, Dexmedetomidine, Esketamine, Depressive Symptoms, Anxiety
What this study did
NCT07120477 · University of Sao Paulo
2026-06-01 – 2029-12 · Suicide Prevention, Ketamine, Crisis Response Plan
What this study did
NCT07888413 · Tianjin Medical University Cancer Institute and Hospital
2026-12-01 – 2029-11-30 · Chronic Pain, Postoperative
What this study did
NCT07377981 · The First Affiliated Hospital with Nanjing Medical University
2026-09-28 – 2029-01-01 · Dexmedetomidine, Ketamine, Analgesia, Respiratory Therapy, Intensive Care Units (ICUs), Agitation, Sedation and Analgesia
What this study did
NCT07836205 · Beijing Chao Yang Hospital
2026-09 – 2028-12 · General Anesthesia-Induced Altered Consciousness
What this study did
NCT07847255 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-10-08 – 2028-09-30 · Critically Ill Adults Requiring Emergency Tracheal Intubation in the Intensive Care Unit
What this study did
NCT05095857 · Copenhagen University Hospital, Rigshospitalet
2023-09-15 – 2028-09-15 · Subarachnoid Hemorrhage, Aneurysmal, Intracerebral Hemorrhage, Traumatic Brain Injury
What this study did
NCT07702240 · Ren Da
2026-11-11 – 2028-03-10 · Biliary Tract Diseases, Procedural Sedation and Analgesia, Hypoxemia, Frailty
What this study did
NCT07525999 · Peking University First Hospital
2026-04 – 2027-12 · Spinal Surgery, Pain Intensity, Dexmedetomidine, Esketamine, Postoperative Analgesia
What this study did
NCT07610343 · Peking University First Hospital
2026-06 – 2027-12 · Older Adults, Cognitive Impairment, Sleep Disorders, Dexmedetomidine, Esketamine
What this study did
NCT07570160 · Nanjing Children's Hospital
2026-06-01 – 2027-11-30 · Behavior Problem
What this study did
NCT07914803 · Peking University First Hospital
2026-11 – 2027-09 · Older Patients, Noncardiac Surgery, Dexmedetomidine, Esketamine, Intranasal Administration, Perioperative Neurocognitive Disorders
What this study did
NCT06399185 · Peking University First Hospital
2024-06-06 – 2027-05 · Urinary Catheter, Catheter-related Bladder Discomfort, Dexmedetomidine, Esketamine
What this study did
NCT07523321 · Peking University First Hospital
2026-04 – 2027-05 · Spinal Surgery, Pain Intensity, Dexmedetomidine, Esketamine, Postoperative Analgesia
What this study did
NCT07308756 · Peking University First Hospital
2026-01-05 – 2027-04 · General Anesthesia, Surgery, Dexmedetomidine, Esketamine, Quality of Recovery
What this study did
NCT07479602 · Peking University First Hospital
2026-04-07 – 2027-02 · Adenotonsillectomy, Children, Intranasal Administration, Dexmedetomidine, Esketamine, Postoperative Pain
What this study did
NCT07063108 · Chinese PLA General Hospital
2025-12-01 – 2026-12-31 · Postoperative Pain
What this study did
NCT06859892 · Peking University First Hospital
2025-03-18 – 2026-12 · Adults, Major Noncardiac Surgery, Dexmedetomidine, Esketamine, Postoperative Sleep Disturbances
What this study did
NCT07523334 · Peking University First Hospital
2026-04 – 2026-12 · Elderly, Noncardiac Surgery, Delayed Neurocognitive Recovery, Postoperative Delirium, Esketamine
What this study did
NCT07748884 · Second Affiliated Hospital of Wenzhou Medical University
2026-08 – 2026-12 · Adverse Respiratory Events, Hypoxemia, Children, Gastroscopy, Esketamine, Remimazolam
What this study did
NCT07179913 · The First Hospital of Jilin University
2026-05-01 – 2026-11-20 · Depressed, Bariatric Surgery
What this study did
NCT06062550 · Peking University First Hospital
2023-10-24 – 2026-10 · Scoliosis Correction, Esketamine, Dexmedetomidine, Postoperative Analgesia, Chronic Postsurgical Pain
What this study did
NCT07644663 · Fudan University
2026-06-09 – 2026-09-10 · Electroencephalogram (EEG), Anesthesia
What this study did
NCT06087510 · Peking University First Hospital
2024-01-24 – 2026-09 · Scoliosis Correction, Postoperative Analgesia, Esketamine, Dexmedetomidine, Chronic Postsurgical Pain
What this study did
NCT07556172 · Second Affiliated Hospital of Nanchang University
2025-01-01 – 2026-06-30 · Sepsis, Mechanical Ventilation
What this study did
NCT06958393 · Qianfoshan Hospital
2025-05-20 – 2026-05-12 · Delirium - Postoperative, Opioid-Free Anaesthesia
What this study did
NCT06853041 · Centre Hospitalier Universitaire de Nice
2025-05-06 – 2026-05-05 · Acute Pain
What this study did
NCT07151716 · Peking University First Hospital
2025-10-21 – 2026-04-24 · Older Patients, Postoperative Care, Intensive Care Unit, Dexmedetomidine, Esketamine, Delirium
What this study did
NCT05950646 · Peking University First Hospital
2024-01-03 – 2026-04-15 · Old Age, Knee Replacement Surgery, Hip Replacement Surgery, Dexmedetomidine, Esketamine, Sleep Quality
What this study did
NCT06822088 · Jinqiao Qian
2025-03-01 – 2026-03-20 · Esketamine, One-lung Ventilation, Oxygenation Indices
What this study did
NCT07145775 · Peking University First Hospital
2025-09-05 – 2026-03-13 · Epidural Analgesia, Labor Pain, Sufentanil, Dexmedetomidine, Esketamine, Ropivacaine
What this study did
NCT04843982 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2021-07-28 – 2026-01-01 · Esketamine, Sepsis, Inflammatory Response, Immunosuppression
What this study did
NCT05826327 · Women's Hospital School Of Medicine Zhejiang University
2023-05-01 – 2025-12-31 · Postpartum Depression
What this study did
NCT06853431 · Second Affiliated Hospital of Wenzhou Medical University
2025-03-01 – 2025-11-30 · Preoperative Anxiety, Preoperative Sedation, Children, Dexmedetomidine, Esketamine, ED95, ED50, Preoperative Sedation of Children
What this study did
NCT05698394 · Peking University First Hospital
2023-09-09 – 2025-11 · Prenatal Depression, Ketamine, Postpartum Depression
What this study did
NCT06579937 · Fujian Provincial Hospital
2024-09-02 – 2025-10-30 · Behavior Problem
What this study did
NCT06778811 · Nanjing First Hospital, Nanjing Medical University
2024-10-11 – 2025-09 · Sleep Wake Disorders, Esketamine and the Quality of Recovery, Dexmedetomidine
What this study did
NCT06566482 · Peking University First Hospital
2024-09-11 – 2025-08-30 · Obstructive Sleep Apnea, Surgery, Dexmedetomidine, Esketamine, Postoperative Sleep Quality
What this study did
NCT05732064 · Peking University First Hospital
2023-05-22 – 2025-07-26 · Breast Cancer, Perioperative Period, Dexmedetomidine, Esketamine, Sleep Quality
What this study did
NCT06729892 · bo xu
2025-01-20 – 2025-05-30 · General Anesthesia With Propofol, Closed-Loop
What this study did
NCT05718024 · Peking University First Hospital
2023-11-01 – 2025-05-23 · Intensive Care Unit, Mechanical Ventilation, Dexmedetomidine, Esketamine, Sleep Quality
What this study did
NCT04964219 · Peking University First Hospital
2022-02-08 – 2025-05-02 · S-ketamine, Postoperative Analgesia, Spine Fusion
What this study did
NCT05922605 · Tao Zhang
2023-06-20 – 2025-05-01 · Postoperative Analgesia, S-ketamine, Pediatrics, Caudal Block, Hypospadias
What this study did
NCT06566469 · Peking University First Hospital
2024-09-02 – 2025-05-01 · Older Patients, Nasal Administration, Dexmedetomidine, Esketamine, General Anesthesia, Emergence Delirium
What this study did
NCT06467513 · Zhang XIao Mei
2024-01-01 – 2025-05 · Heart Diseases, Heart Valve Diseases
What this study did
Early phase / not applicable (107)
Major Depressive Disorder
NCT07422519 · Hospital Universitari Vall d'Hebron Research Institute
2025-09-18 – 2026-12-15 · Depression - Major Depressive Disorder, Depression Disorder, Depression Chronic, Treatment-Resistant Major Depressive Disorder
What this study did
NCT06431386 · The Royal's Institute of Mental Health Research
2024-06-11 – 2025-09-17 · Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major, Bipolar Disorder
What this study did
NCT04843462 · Lukas Pezawas
2021-04-29 – 2023-04-14 · Major Depressive Disorder, Therapy Resistant Depression
What this study did
NCT04847245 · Peking University
2021-05-01 – 2023-03-01 · Chronic Visceral Pain, Major Depressive Disorder
What this study did
NCT04399070 · Yan Qiu
2020-08-01 – 2021-01-31 · Depression, Bipolar, Depression, Unipolar, Major Depressive Disorder, Manic-Depressive - Now Depressed
What this study did
Other / comorbidity
NCT06468436 · Peking University First Hospital
2025-11 – 2030-12-01 · Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine, Esketamine, Delirium
What this study did
NCT03756961 · Göteborg University
2019-05-01 – 2029-12-31 · Obesity, Pain, Postoperative
What this study did
NCT07396220 · University of California, San Diego
2026-01-09 – 2029-01 · Suicidal Ideation
What this study did
NCT07002801 · Harbin Medical University
2025-05-14 – 2028-10-10 · Gastrointestinal Disease
What this study did
NCT07935252 · Beijing Tiantan Hospital
2026-11-10 – 2028-04-01 · Acute and Chronic Postsurgical Pain
What this study did
NCT06788444 · Beijing Tiantan Hospital
2025-02-08 – 2027-12-31 · Irritable Bowel Syndrome
What this study did
NCT07699523 · China-Japan Friendship Hospital
2026-07-14 – 2027-12-30 · Depth of Anesthesia Monitoring, BIS-EEG
What this study did
NCT07916051 · Anhui Provincial Hospital
2026-10-30 – 2027-10-30 · Cesarean Section (MeSH: D002585), Postoperative Pain After Cesarean Section, Enhanced Recovery After Surgery
What this study did
NCT07597486 · Tianjin Medical University General Hospital
2026-05-15 – 2027-09-30 · Senile Pruritus
What this study did
NCT07641673 · The Second Hospital of Anhui Medical University
2026-06 – 2027-09 · Thyroidectomy, Coughing Reflex
What this study did
NCT07625826 · The Second Hospital of Anhui Medical University
2026-12 – 2027-09 · Thyroidectomy, Coughing Reflex
What this study did
NCT07560722 · Tianjin Medical University General Hospital
2026-05-05 – 2027-08-11 · Intrahepatic Cholestasis of Pregnancy
What this study did
NCT07736352 · China-Japan Friendship Hospital
2026-07-30 – 2027-07-31 · Knee Osteoarthritis, Replacement, Knee, Elective Surgical Patients, ASA Class I/II Patients
What this study did
NCT06817239 · Nanfang Hospital, Southern Medical University
2025-02-12 – 2027-07 · Delirium in Old Age, Delirium, Postoperative, Anesthesia, Cognitive Dysfunction, Pain, Postoperative, Esketamine, Non-cardiac Surgery
What this study did
NCT06773143 · Nanjing First Hospital, Nanjing Medical University
2024-12-30 – 2027-04-30 · Insomnia, Breast Cancer Surgery, Esketamine
What this study did
NCT07760740 · Tianjin Medical University General Hospital
2026-08-15 – 2027-04-20 · Cholestatic Pruritus
What this study did
NCT06778460 · West China Hospital
2023-05-05 – 2027-03-31 · Postoperative Chronic Pain
What this study did
NCT07367542 · Chinese PLA General Hospital
2026-01-17 – 2027-02-01 · Depression, Anxiety, S-ketamine, Breast Cancer
What this study did
NCT07374198 · Chinese PLA General Hospital
2026-01-18 – 2027-02-01 · Depression, Anxiety, S-ketamine, Breast Cancer
What this study did
NCT07374211 · Chinese PLA General Hospital
2026-01-18 – 2027-02-01 · Depression, Anxiety, S-ketamine, Breast Cancer
What this study did
NCT07665099 · Xijing Hospital
2026-07-01 – 2027-01-31 · Perioperative Neurocognitive Disorders
What this study did
NCT07374458 · Nanjing First Hospital, Nanjing Medical University
2026-02-01 – 2026-12-31 · Post Induction Hypotension
What this study did
NCT07315074 · Zhuan Zhang
2026-03-01 – 2026-12-31 · Circadian Rhythm, Postoperative Sleep Disturbance
What this study did
NCT07880938 · The First Hospital of Jilin University
2026-09 – 2026-12 · Emergence Agitation, Vocal Cord Polyps
What this study did
NCT07584902 · Gang Chen
2026-04-27 – 2026-10-31 · Biliary and Pancreatic Diseases, Endoscopic Retrograde Cholangiopancreatography (ERCP)
What this study did
NCT06914193 · Beijing Tiantan Hospital
2025-04-01 – 2026-10-01 · Postherpetic Neuralgia
What this study did
NCT06890897 · Beijing Tiantan Hospital
2025-04-01 – 2026-09-30 · Zoster; Herpes, Trigeminal Neuralgia (Etiology)
What this study did
NCT06900205 · RenJi Hospital
2025-04-01 – 2026-09-30 · Postoperative Delirium (POD), Postoperative Sleep Disturbance
What this study did
NCT07230171 · Beijing Tiantan Hospital
2025-09-15 – 2026-08-30 · Fibromyalgia, Pregabalin, Esketamine
What this study did
NCT05212571 · Erasmus Medical Center
2022-04-19 – 2026-08-20 · Complex Regional Pain Syndromes, CRPS (Complex Regional Pain Syndromes)
What this study did
NCT06914206 · Beijing Tiantan Hospital
2025-04-01 – 2026-07-01 · Herpes Zoster
What this study did
NCT06914180 · Beijing Tiantan Hospital
2025-04-01 – 2026-07-01 · Postherpetic; Neuralgia, Trigeminal (Etiology)
What this study did
NCT06389344 · Beijing Tiantan Hospital
2024-05-20 – 2026-06-30 · Esketamine, Consciousness Disorders
What this study did
NCT07002723 · Peking University Shenzhen Hospital
2025-06-20 – 2026-06-30 · Hip Fractures
What this study did
NCT07131033 · The Second People's Hospital of Huai'an
2025-09-01 – 2026-06-01 · Laparoscopic Cholecystectomy, Alleviate Postoperative Fatigue Syndrome
What this study did
NCT06896994 · Beijing Tiantan Hospital
2025-04-01 – 2026-05-01 · Postherpetic Neuralgia
What this study did
NCT07125573 · First Affiliated Hospital of Kunming Medical University
2025-05-01 – 2026-04-01 · Esketamine Plus Dexmedetomidine Affect Postoperative Quality, Thoracoscopy, Lung Neoplasms
What this study did
NCT06531837 · Beijing Tiantan Hospital
2024-08-25 – 2026-02-28 · Chronic Pain
What this study did
NCT06624878 · Zhejiang Cancer Hospital
2024-10-08 – 2026-02-14 · Ovarian Cancer, Cytoreductive Surgery, Depressive Symptom
What this study did
NCT06543563 · Beijing Tiantan Hospital
2024-08-09 – 2026-01-31 · PD - Parkinson's Disease, Deep Brain Stimulation, Esketamine
What this study did
NCT06451627 · Beijing Tiantan Hospital
2024-06-10 – 2026-01-28 · Esketamine, Sleep Disturbance, Spinal Surgery
What this study did
NCT06976996 · Northern Jiangsu People's Hospital
2025-03-16 – 2025-12-15 · Quality of Postoperative Recovery
What this study did
NCT06199011 · The Second Hospital of Anhui Medical University
2024-01-01 – 2025-12-01 · Depressive Symptoms
What this study did
NCT07062601 · Anqing Municipal Hospital
2025-07-10 – 2025-11-15 · Etomidate, Esketamine, Tonsillectomy, Children
What this study did
NCT06355180 · Capital Medical University
2024-04-16 – 2025-08-28 · Mood Disorders, Suicidal Ideation, Depressive Episode
What this study did

Competitive landscape

This mechanism is crowded: 11 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Major Depressive Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Esketamine (Spravato): this drugApprovedSmall moleculeNMDA receptorPartial signal
NCT02418585: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88)
NCT02417064: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine 56 mg Plus Oral Antidepressant -19 Units on a scale (Standard Deviation 13.86) | Intranasal Esketamine 84 mg Plus Oral AD -18.8 Units on a scale (Standard Deviation 14.12) vs Oral AD Plus Intranasal Placebo -14.8 Units on a scale (Standard Deviation 15.07) missed
Amantadine ER (Gocovri / ADS-5102)
Approved(overall)
Small moleculeNMDA receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT01360645: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6)
NCT01360632: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14): Brexpiprazole (1mg) + ADT -7.65 Units on a scale (Standard Error 0.5) | Brexpiprazole (3mg) + ADT -7.98 Units on a scale (Standard Error 0.51) vs Placebo + ADT -6.45 Units on a scale (Standard Error 0.51)
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Partial signal
NCT03738215: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) (Baseline and Week 6): Cariprazine 1.5 mg/Day + ADT -14.1 score on a scale (Standard Error 0.7) | Cariprazine 3 mg/Day + ADT -13.1 score on a scale (Standard Error 0.7) vs Placebo + ADT -11.5 score on a scale (Standard Error 0.7)
Dextromethorphan / Bupropion (Auvelity)ApprovedSmall moleculesigma-1/NMDA, Dopamine/norepinephrine transporterPartial signal
NCT04019704: Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862)
NCT02741791: Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 missed
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorWeak signal
NCT05061706: Montgomery-Asberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 units on a scale (Standard Error 0.56) | Placebo -10.2 units on a scale (Standard Error 0.54)
NCT04985942: Montgomery-Åsberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 score on a scale (Standard Error 0.54) | Placebo -9.8 score on a scale (Standard Error 0.53)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Vortioxetine (Trintellix)ApprovedSmall moleculeSerotonin transporter + multiple 5-HT receptorsPartial signal
NCT00596817: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator (Within first 24 weeks of the double-blind period): Vortioxetine: 5 or 10 mg 13.2 percentage of patients who relapsed vs Placebo 26 percentage of patients who relapsed
NCT02709655: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (Baseline (Week 4 of Phase A), Week 8 of Phase B): Double-Blind: Vortioxetine 10 mg -19.2 units on a scale (Standard Error 1.37) | Double-Blind: Vortioxetine 20 mg -19.94 units on a scale (Standard Error 1.37) vs Double-Blind: Placebo -17.48 units on a scale (Standard Error 1.35) | Double-Blind: Fluoxetine 20 mg -20.78 units on a scale (Standard Error 1.6) missed
AmmoxetinePhase 3Small moleculeSerotonin/norepinephrine transporterPartial signal
NCT06827431: Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27).
Ansofaxine HydrochloridePhase 3Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT04853407: MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001).
AzetukalnerPhase 3Small moleculeKv7 potassium channelnot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
DeupsilocinPhase 3Small molecule5-HT2A receptorPartial signal
NCT05385783: Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151)
KH607Phase 3Small moleculeGABA-A receptorPartial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)
Phase 3(overall)
Small moleculeDopamine D2/D3 receptor + 5-HT7 receptornot yet gradedNo reviewed efficacy summary in this indication
Lysergide Tartrate (LSD) (DT120)Phase 3Small molecule5-HT2A receptorReliable signal
NCT06941844: Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001.
Milsaperidone (VHX-896)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
OsavampatorPhase 3Small moleculeAMPA receptor (positive allosteric modulator)Partial signal
NCT05203341: MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082).
Psilocybin (COMP360)Phase 3Small molecule5-HT2A receptorReliable signal
NCT05711940: COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001.
NCT05624268: Change in MADRS total score from baseline to Week 6 (COMP005 trial): COMP360 25 mg vs placebo, mean treatment difference -3.6 points (95% CI -5.7 to -1.5; p<0.001)
SeltorexantPhase 3Small moleculeOrexin-2 receptor (OX2R)Partial signal
NCT04533529: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26)
NCT04513912: Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance missed
Solriamfetol (Sunosi)Phase 3Small moleculeDopamine/norepinephrine transporterPartial signal
NCT06360419: In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. missed
D-Cycloserine / Lurasidone (NRX-101)Phase 2/3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
Mitizodone PhosphatePhase 2/3Small moleculeSerotonin transporter/5-HT receptorWeak signalNo reviewed efficacy summary in this indication
ACP-211Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancerPartial signal
NCT05117632: MADRS reduction at Week 6: 15.5 points (biomarker-defined group) vs 10.6 points (biomarker-negative group); clinical response (>=50% MADRS reduction): 61% vs 33%
ALTO-203Phase 2Small moleculeHistamine H3 receptor (antagonist / inverse agonist)Partial signalNo reviewed efficacy summary in this indication
ALTO-300Phase 2Small moleculeMelatonergic (MT) receptors (agonist) + serotonin receptorWeak signalNo reviewed efficacy summary in this indication
Arketamine (PRT042)Phase 2Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
AV-101Phase 2Small moleculeNMDA receptorPartial signal
NCT02484456: Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) missed
BI 1569912Phase 2Small moleculeNMDA receptorPartial signal
NCT06558344: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) missed
NCT06280235: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.): 5 mg BI 1569912 -7.8 units on a scale (95% CI -11 to -4.6) | 10 mg BI 1569912 -11.9 units on a scale (95% CI -15 to -8.7) | 20 mg BI 1569912 -12.3 units on a scale (95% CI -14.6 to -10) vs Placebo -12 units on a scale (95% CI -14.2 to -9.7) missed
BlixeprodilPhase 2Small moleculeNMDA receptorWeak signalFeatured results are safety only in this race
BPL-003 (mebufotenin Benzoate)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05870540: MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025).
BretisilocinPhase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
Cyclobenzaprine (Tonmya)Phase 2Small molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)not yet gradedNo reviewed efficacy summary in this indication
DT-101Phase 2Small moleculeAMPA receptor (positive allosteric modulator)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
Emestedastat (Xanamem)Phase 2Small molecule11-beta-HSD1Partial signal
NCT05657691: Primary endpoint (Attention Composite cognitive score, week 6) missed: least squares mean change 0.32 (emestedastat) vs 0.46 (placebo), difference -0.13 (95% CI -0.32 to 0.06), p=0.17 favouring placebo. (MADRS depression score was only a secondary endpoint, borderline at p=0.05.) missed
Esketamine (CLE-100)Phase 2Small moleculeNMDA receptorPartial signal
NCT06340958: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) missed
NCT04103892: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Part B - CLE-100 (Oral Esketamine) -10.72 units on a scale (Standard Error 1.13) vs Part B - Placebo -9.46 units on a scale (Standard Error 1.31) missed
EvifacotrepPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ForvisirvatPhase 2Small moleculeSIRT6Partial signal
NCT04479852: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) missed
GlyphAllo (allopregnanolone Prodrug) (SPT-300)Phase 2Small moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
GW117Phase 2Small moleculeMelatonin MT1/MT2 receptor + 5-HT2C receptorPartial signal
NCT06796868: Change in HAMD-17 total score from baseline at Week 8 (FAS, n=276): placebo -13.46, GW117 20mg -14.62, 40mg -14.34, 60mg -13.75; numerically greater reductions with GW117 but not statistically significant vs placebo. missed
HS-10353Phase 2Small moleculeGABA-A receptorWeak signal
NCT05195203: Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses
Hypidone (YL-0919)Phase 2Small moleculeSerotonin transporter/5-HT1A receptor/sigma-1 receptorPartial signalNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
JNJ-89495120Phase 2Small moleculeMuscarinic M1 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LiafensinePhase 2Small moleculeSerotonin/norepinephrine/dopamine transporterReliable signal
NCT05113771: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31)
NCT01369095: In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). missed
LV232Phase 2Small moleculeSerotonin transporter + 5-HT3 receptorWeak signalNo reviewed efficacy summary in this indication
Mebufotenin (5-MeO-DMT) (GH001)Phase 2Small molecule5-HT2A receptorPartial signal
NCT05800860: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001)
NelivaptanPhase 2Small moleculeVasopressin V1B receptorPartial signal
NCT00358631: Change from baseline to Day 56 in HAM-D-17 total score (LS mean, SE): nelivaptan 250mg BID -10.7 (0.94) vs placebo -7.68 (0.95); difference from placebo -3.03 (95% CI -5.66 to -0.39; p=0.0244). 100mg BID nelivaptan and escitalopram 10mg QD arms did not separate from placebo.
NH102Phase 2Small moleculeSerotonin/norepinephrine/dopamine transporter + 5-HT2A receptorPartial signalNo reviewed efficacy summary in this indication
PDC-1421Phase 2BotanicalPolygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)Partial signal
NCT02395978: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61)
Pramipexole / Ondansetron (ALTO-207)Phase 2Small moleculeDopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptornot yet gradedNo reviewed efficacy summary in this indication
RopanicantPhase 2Small moleculeAlpha4beta2 nicotinic acetylcholine receptorPartial signal
NCT06836063: MADRS total score change from baseline vs placebo at Week 6: mean difference -3.572 (FAS, p=0.038), -4.067 (PP set, p=0.023) -- primary endpoint met.
NCT03155503: Safe and well tolerated in healthy subjects at single doses up to 60 mg and multiple doses up to 45 mg once daily. Pharmacokinetics were nonlinear with accumulation on multiple dosing: 1.5- to 2.5-fold higher maximum concentration and 1.6- to 4.0-fold higher AUC from 0 to 24 h on day 14 compared with day 1.
SPN-820Phase 2Small moleculemTORC1Partial signal
NCT05066672: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (Baseline to Week 4): NV-5138 (800 or 1600 mg) -12.2 units on a scale (Standard Deviation 9.66) | Placebo -11.6 units on a scale (Standard Deviation 10.64) missed
SPN-821Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (activator)not yet gradedNo reviewed efficacy summary in this indication
VLS-01Phase 2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ZelquistinelPhase 2Small moleculeNMDA receptorPartial signal
NCT03726658: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) missed
ELE-101Phase 1/2Small molecule5-HT2A receptornot yet gradedNo reviewed efficacy summary in this indication
ALA-3000Phase 1Small moleculeNMDA receptorPartial signalFeatured results are safety only in this race
ApimostinelPhase 1Small moleculeNMDAR agonist/modulatorWeak signalFeatured results are safety only in this race
ENX-104Phase 1Small moleculeDopamine D2/D3 receptor (antagonist)Weak signalNo reviewed efficacy summary in this indication
LY03021Phase 1Small moleculeNorepinephrine/dopamine transporter + GABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
SP-101Phase 1Small moleculeNMDA receptornot yet gradedNo reviewed efficacy summary in this indication
Itruvone
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Fluoxetine (Symbyax)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); serotonin transporter (reuptake inhibitor)Reliable signal
NCT00035321: Primary endpoint, mean change in MADRS total score at 8 weeks (LOCF): Study 1 olanzapine/fluoxetine -11.0 vs fluoxetine -9.4 vs olanzapine -10.5, no statistically significant difference; Study 2 -14.5 vs -8.6 (p < .001) and -7.0 (p < .001); pooled -12.7 vs -9.0 (p < .001) and -8.8 (p < .001) (Thase et al., J Clin Psychiatry 2007).
OnfasprodilDiscontinuedSmall moleculeNMDA receptorPartial signal
NCT05454410: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score 24 Hours (Day 2) After Injection (Baseline and 24 hours after SC injection): MIJ821 10 mg -14.1 Scores on a Scale (Standard Error 1.95) | MIJ821 4 mg -11.4 Scores on a Scale (Standard Error 2.04) | MIJ821 1 mg -8.4 Scores on a Scale (Standard Error 2.02) vs Placebo -8.9 Scores on a Scale (Standard Error 1.82)
NCT03756129: Change From Baseline in the Total Score of the Montgomery Asberg Depression Rating Scale (MADRS) at 24 Hrs (Baseline, and at 24 hours): Pooled MIJ821 0.16 mg/kg -15.51 Scores on a Scale (Standard Error 1.9) | Pooled MIJ821 0.32 mg/kg -12.98 Scores on a Scale (Standard Error 1.9) vs Ketamine 0.5 mg/kg Weekly -12.94 Scores on a Scale (Standard Error 2.7) | Placebo Weekly -7.27 Scores on a Scale (Standard Error 1.9)

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Spravato (Esketamine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
February 2027 (1)
Early phase / not applicableAutism Spectrum DisorderRecruiting
Est. primary completion 2027-02-01 · NCT07324057 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Major Depressive DisorderRecruiting
Est. primary completion 2027-04 · NCT06278779 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Postherpetic Neuralgia, Esketamine, Dexmedetomidine, Intranasal Administration, Analgesic EfficacyNot yet recruiting
Est. primary completion 2027-11 · NCT07934901 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Major Depressive DisorderRecruiting
Est. primary completion 2027-12-15 · NCT06103760 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2028-12-27 · NCT07716098 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
Phase 4Parturients, Depressive Symptoms, Esketamine, Dexmedetomidine, Intranasal Administration, Postpartum DepressionNot yet recruiting
Est. primary completion 2029-10 · NCT07639099 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 3DepressionRecruiting
Est. primary completion 2030-12-31 · NCT06713616 · CT.gov ↗
What to watch
2031 (1)
April 2031 (1)
Phase 3Major Depressive DisorderRecruiting
Est. primary completion 2031-04-09 · NCT07227454 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 January 2025ApprovalFDA approves SPRAVATO as monotherapy for treatment-resistant depression
US, FDA · Source ↗
21 January 2025Priority reviewApproval followed FDA Priority Review
US, FDA · Source ↗